Arcutis Biotherapeutics (ARQT) reported $376M in revenue for fiscal 2025, +91.3% year on year. That ranks #2383 by revenue among 2853 SEC filers and #236 in Healthcare. It posted a net loss of −$16.1M for the same year. The fiscal 2025 balance sheet shows $433M in total assets, $42.9M in cash and $108M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $376M | +91.3% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$12.2M | +$116M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$16.1M | +$124M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$5.6M | +$107M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $686,000 | +379.7% | FY20252025-12-31 |
| Total assetsAssets | $433M | +24.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $189M | +20.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $42.9M | −39.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $108M | +0.7% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $105M | −$11.3M | Open → |
| Q2 20262026-06-30 | $130M | $15.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Arcutis Biotherapeutics, Inc.
- Ticker
- ARQT
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001787306
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| CaredxCDNA | $380M | −$21.4M |
| Twist BioscienceTWST | $377M | −$77.7M |
| Pharming GroupPHAR | $376M | $2.9M |
| Arcutis BiotherapeuticsARQT | $376M | −$16.1M |
| InmodeINMD | $370M | $93.8M |
| MannkindMNKD | $349M | $5.9M |
| InogenINGN | $349M | $22.7M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Arcutis Biotherapeutics — Key figures |url=https://companiesranked.com/en/company/arcutis-biotherapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Arcutis Biotherapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/arcutis-biotherapeuticsBibTeX
@misc{companiesranked-en-company-arcutis-biotherapeutics-2026,
author = {{CompaniesRanked}},
title = {{Arcutis Biotherapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/arcutis-biotherapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001787306-26-000018 · February 25, 2026
{{cite web |title=Arcutis Biotherapeutics — Key figures — 10-K (0001787306-26-000018) |url=https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.